Aquestive therapeutics, inc. (AQST)
CashFlow / Yearly
Dec'19Dec'18Dec'17
Cash flows from operating activities:
Net loss

-66,246

-61,376

-8,943

Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation and amortization

2,905

3,236

-

Depreciation and amortization

-

-

3,750

Change in fair value of warrant

0

5,278

1,123

Share-based compensation

7,071

29,940

0

Asset retirement obligation accretion

-

-

122

Amortization of intangible

-

-

51

Amortization of debt issuance costs and discounts

1,929

1,696

1,860

Loss on the extinguishment of debt

-4,896

0

-

Non-cash interest expense

359

237

33

Recoveries of amounts previously reserved

-

-

53

Other, net

-

-

0

Changes in operating assets and liabilities:
Trade receivables and other receivables

6,815

409

-4,691

Inventories, net

-2,582

1,427

1,128

Prepaid expenses and other current assets

1,366

1,140

-

Prepaid expenses and other current assets

-

-

171

Accounts payable

-7,872

11,319

2,943

Accrued expenses

746

281

1,001

Deferred revenue

1,601

-626

545

Net cash used for operating activities

-60,210

-12,991

5,824

Cash flows from investing activities:
Capital expenditures

663

1,824

2,068

Net cash used for investing activities

-663

-1,824

-2,068

Cash flows from financing activities:
Net proceeds from initial public offering

39,317

68,830

0

Cash received for warrant exercise

-

-

24

Proceeds from issuance of debt

70,000

0

5,000

Debt repayment

50,000

0

-

Payments for financing costs

3,946

4,768

610

Premium paid to retire debt

2,944

0

-

Payments for taxes on share-based compensation

2,827

6,027

0

Net cash used for financing activities

49,600

58,035

4,414

Net decrease in cash and cash equivalents

-11,273

43,220

-

Net increase in cash and cash equivalents

-

-

8,170

Supplemental disclosures of cash flow information:
Cash payments for interest

7,340

6,049

5,814

Increase (decrease) in future cash outflow to pay for purchases of fixed assets that have occurred.

104

104

-

Increase (decrease) in future cash outflow to pay for purchases of fixed assets that have occurred.

-

-

20

Increase (decrease) in future cash outflow to pay for deferred offering costs that have occurred.

0

-588

588

Future cash outflows to pay for preferred dividends.

-

-

2,480

Withholding tax payments accrued on share based compensation.

0

2,515

0

Amount of deferred costs charged to additional paid in capital (APIC).

540

5,232

0

The amount of warrants issued in connection with long-term debt as part of a noncash transaction.

6,800

0

-

The amount of warrants exercised as part of a noncash transaction.

0

12,952

0